5-ethyl-3-methoxy-isoxazole | 26347-22-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-ethyl-3-methoxy-isoxazole
• 英文别名: 5-Ethyl-3-methoxy-1,2-oxazole
• CAS: 26347-22-8
• 化学式: C₆H₉NO₂
• 分子量: 127.143
• InChiKey: OSKWHSOCSWSDCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] NEPRILYSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA NÉPRILYSINE
  申请人：THERAVANCE BIOPHARMA R & D IP LLC

  公开号：WO2015116786A1

  公开（公告）日：2015-08-06

  In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一方面，本发明涉及具有公式（I）的化合物：其中R1-R6定义如说明书中所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Substituted Benzamide Compounds
  申请人：Reich Melanie

  公开号：US20120071461A1

  公开（公告）日：2012-03-22

  Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

  对应于式(I)的取代苯甲酰胺化合物，其中R5、R6、R7、R8、a、b、c、d、t、D和X具有定义的含义，其制备方法，包括这些化合物的药物组合物，以及使用这些化合物治疗疼痛和其他至少部分通过激肽酶1受体介导的疾病的方法。
• [EN] 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE 5-BIPHÉNYL-4-HÉTÉOARYLCARBONYLAMINO-PENTANOÏQUE UTILISÉS EN TANT QU'INHIBITEURS DE NÉPRILYSINE
  申请人：THERAVANCE BIOPHARMA R & D IP LLC

  公开号：WO2015116760A1

  公开（公告）日：2015-08-06

  In one aspect, the invention relates to compounds having the formula (I): where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一个方面，该发明涉及具有以下式（I）的化合物：其中R1、R2a、R2b和R3-R6如规范中定义，或其药学上可接受的盐。这些化合物具有神经肽酶抑制活性。在另一个方面，该发明涉及包括这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS
  申请人：Arvinas, Inc.

  公开号：US20160272639A1

  公开（公告）日：2016-09-22

  The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

  本发明涉及双功能化合物，其作为靶向泛素化的调节剂具有实用性，特别是本发明的双功能化合物可以抑制多种蛋白质和其他蛋白质，这些蛋白质通过本发明的双功能化合物被降解和/或被抑制。具体而言，本发明涉及一端含有结合泛素连接酶的VHL配体，另一端含有结合靶蛋白的基团，使得靶蛋白靠近泛素连接酶，从而降解（和抑制）该蛋白质。本发明展示了与本发明化合物相关的广泛的药理活性，与靶向多肽的降解/抑制一致。
• CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM
  申请人：Shionogi & Co., Ltd

  公开号：EP3744721A1

  公开（公告）日：2020-12-02

  Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)': wherein A is S or O; R1a is substituted or unsubstituted alkyloxy or the like, R2a to R2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R3 is each independently halogen or the like, r is an integer of 0 to 4, R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.

  提供了具有 D3 受体拮抗作用的新型化合物。 由式（IA）'代表的化合物： 其中 A 是 S 或 O；R1a 是取代或未取代的烷氧基或类似物；R2a 至 R2d 各自独立地是氢原子或类似物；环 B 是 4 至 8 元非芳族碳环或类似物；R3 各自独立地是卤素或类似物；r 是 0 至 4 的整数；R4 是取代或未取代的芳族杂环或类似物、 或其药学上可接受的盐。